clinical development plan and financial terms relating to ISIS-TTRRx to reflect an accelerated development plan for that antisense drug...Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...Shares of Northwest (NASDAQ:NWBO) fell 13 cents to close Thursday at $3.77.

The latest round is expected to support ongoing clinical development of lead candidate, LiRIS (lidocaine releasing intravesical system), in development for patients with interstitial cystitis.

at the same unit price.

UCB also picked up clinical development and commercialization costs. (See BioWorld Today, May 11, 2006.) In 2009, the companies reported results from a Phase IIb dosing study of the drug showing a 24.9 percent treatment advantage over placebo in systemic lupus erythematosus (SLE) patients...Closing of the private placement is subject to customary conditions, including acceptance by the TSX Venture Exchange.

The transaction is expected to close on Feb. 19.

The company will receive proceeds of $8 million, which it expects to use to fund clinical trials and for working capital and general corporate purposes.

Together, the three collaborated in the seminal discovery of the first biologically active stapled peptide and translation into a potential clinical application...Proceeds from any offering are expected to support general corporate purposes, including to R&D costs, payment obligations and capital expenditures.

As a small biotech with one foot in infectious disease and the other in neurology while having one hand in commercial products and the other in clinical development, "we have a unique strategy, and so far it's working well," Musunuri said...Proceeds will be used for general corporate purposes, including the company's ongoing trials of NX-1207, in late-stage development for benign prostatic hyperplasia and in Phase II testing in prostate cancer.

The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

The Series D enables Zafgen to move clinical and regulatory activities forward without the distraction of additional fundraising, Hurwitz added...Proceeds will support a Phase III trial of Multikine (leukocyte interleukin, injection).

The company laid groundwork for clinical trials in advance of the financing and plans to begin a "very substantial" randomized Phase II study in the U.S...The company also received $25.0 million from the sale of common stock in a private placement to strategic partner AstraZeneca plc, of London, that closed concurrently with the IPO, and $5.0 million from the sale of a convertible note to research collaborator Biogen Idec Inc., of Weston, Mass., which was converted into shares of common stock at

The study, by scientists at the National Cancer Institute, and colleagues, appeared in Cancer Research.

Thus, Calderon said she "would recommend requiring clinical studies to fully evaluate the abuse potential" of products submitted for review that exceed that level

KaloBios has three mAbs at the clinical development stage...Shares of Cell Therapeutics (NASDAQ:CTIC) dropped 51 cents, or 25 percent, to close Friday at $1.53.

Clinical trials now represent an aggregate expense of approximately $31.3 billion, or nearly 40 percent of the R&D budget of major drug developers – much of that due to systemic inefficiency, according to the report...362, has been introduced in the Senate.

is acting as sole book-running manager.

The FDA did not cite clinical safety or efficacy issues and did not request additional pre-approval studies, but the agency did raise questions relating to chemistry, manufacturing and controls, as well as issues related to a facility inspection at a third-party manufacturer. (See BioWorld Today, March 28, 2012.) The company completed an end-of-review meeting with the FDA in June to seek clarity from the agency in developing its response...LLC acted as joint book-running managers, with Needham

The company plans to use the proceeds to complete clinical development of lead candidate dalbavancin, currently in a second pivotal Phase III trial in skin infections, and to fund commercialization activities in the U.S...LLC and CRT Capital Group LLC served as initial purchasers in the private placement. (See BioWorld Today, March 1, 2012.)